, Tracking Stock Market Picks
Enter Symbol:
Arena Pharmaceuticals, Inc. (ARNA) [hlAlert]

down 58.97 %

Arena Pharmaceuticals, Inc. (ARNA) rated Buy with price target $14 by Needham

Posted on: Wednesday,  Aug 6, 2008  9:25 AM ET by Needham

Needham rated Buy Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) on 08/06/2008, when the stock price was $6.46. Since
then, Arena Pharmaceuticals, Inc. has lost 58.98% as of 10/08/2015's recent price of $2.65.
If you would have followed this Needham's recommendation on ARNA, you would have lost 58.97% of your investment in 2619 days.

Arena Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory, and metabolic diseases. Arena's most advanced product candidate, lorcaserin, is being investigated in a Phase three clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds targeting G protein-coupled receptors, an important class of validated drug targets, includes compounds being evaluated independently and with its partners, Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.

Needham & Company, LLC focuses on emerging growth companies in technology, biotechnology and life sciences. The firm's research goal is to service the needs of growth-oriented institutional clients. Needham & Company has established itself as a premier specialty investment bank providing timely and valuable analysis on companies that are under-covered by the majority of Wall Street firms.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/6/2008 9:25 AM Buy
6.46 14.00
as of 12/24/2008
1 Week down  -4.65 %
1 Month down  -39.55 %
3 Months down  -26.78 %
1 YTD down  -41.00 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy